Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients

BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients. METHODS:...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kim, Jeong Han, Ko, Soon Young, Choe, Won Hyeok, Kwon, So Young, Lee, Chang Hong
Médium: Artigo
Jazyk:Inglês
Vydáno: The Korean Association for the Study of the Liver 2013
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3796677/
https://ncbi.nlm.nih.gov/pubmed/24133665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2013.19.3.273
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky